Table 3.
IGF-1 levels and type of therapy by mechanism of action.
| Type of Therapy/IGF-1 Levels in nmol/L | DA (n1 = 3; n2 = 4) |
SSA (n1 = 42; n2 = 87) |
GHRA (n1 = 3; n2 = 5) | GHRA + DA (n1 = 0; n2 = 2) |
SSA + GHRA (n1 = 14; n2 = 19) |
SSA + GHRA + DA (n1 = 1; n2 = 3) |
SSA + DA (n1 = 7; n2 = 10) |
No Treatment (n1 = 12; n2 = 39 |
p Value |
|---|---|---|---|---|---|---|---|---|---|
| IGF-1 levels at the previous hospitalization | 15.50 | 18.65 (95% CI 14.092–23.508) |
46.40 | - | 18.80 (95% CI 16.135–27.999) |
70.20 | 28.90 (95% CI 10.499–69.222) |
27.00 (95% CI 18.142–32.044) |
0.264 * |
| IGF-1 levels at the current hospitalization | 19.65 | 23.10 (95% CI 19.788–27.216) |
47.10 | 22.65 | 26.60 (95% CI 14.735–29.389) |
13.80 | 30.35 (95% CI 20.48–70.918) |
23.60 (95% CI 18.96–34.508) |
0.2124 * |
* (not statistically significant). n1—number of patients at the previous hospitalization; n2—number of patients at the current hospitalization in 2021. The IGF-1 levels were available for some of the observed patients.